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ABSTRACT 22 
Objectives: The main objective was to investigate Y-site compatibility of intravenous drugs 23 
with one standard TPN admixture for preterm infants. Since micro-precipitation was observed 24 
in the water phase after addition of trace elements, the concentration effect on micro-25 
precipitation formation developed as a sub goal. 26 
Methods: Seven drugs (ampicillin, ceftazidime, fluconazole, fosphenytoin, furosemide, 27 
metronidazole and paracetamol) were mixed in three mixing ratios with one preterm TPN 28 
admixture. Samples were investigated within one hour and again after four hours. Precipitation 29 
was studied in a lipid-free version called TPNaq by light obscuration, turbidimetry and visual 30 
examination. Emulsion stability data was assessed by light obscuration and laser diffraction. 31 
pH was measured to assess theoretical risk of precipitation and emulsion destabilization. The 32 
influence of different concentrations of trace elements on precipitation was investigated by 33 
visual examination, turbidimetry and light obscuration.  34 
Results: Ampicillin, ceftazidime, fosphenytoin and furosemide lead to precipitation after 35 
mixing with TPNaq. In some samples of TPN and fluconazole, metronidazole and paracetamol, 36 
the emulsion droplet size was above the acceptance limit, although this might also be inherent 37 
to the TPN admixture. An unexpected formation of micro-precipitate correlating to increasing 38 
amounts of added trace elements, might be caused by an interaction of cysteine and copper, 39 
and complicated the compatibility assessment with drugs. 40 
Conclusions: The micro-precipitate resulting from addition of trace element should be 41 
investigated further. This study did not provide sufficient evidence to recommend Y-site 42 
 3 
infusion of the tested drugs and the preterm admixture; however it might offer some additional 43 
support to other compatibility data. 44 
 45 
Key words: y-site compatibility, TPN, total nutrition admixture, copper, cysteine, emulsion 46 
stability, precipitation, trace elements.. 47 
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KEY MESSAGES 49 
What is already known on this subject  50 
• TPN admixtures are complex blends and Y-site infusion of incompatible combinations 51 
of drugs and TPN might cause precipitation of particles or destabilization of the lipid 52 
emulsion, both presenting risk of emboli if infused into the blood circulation.  53 
• There is a lack of documented compatibility data for many drugs and TPN 54 
combinations, especially for doses, products and infusion regimes relevant for infants 55 
and children, and extrapolation of data generated for the adult population should be 56 
done with great care.  57 
What this study adds  58 
• Preliminary compatibility data adopted for preterm infants for seven drugs (ampicillin, 59 
ceftazidime, fluconazole, fosphenytoin, furosemide, metronidazole and paracetamol) 60 
with a preterm infant TPN formulation.  61 
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• The complexity of parallel infusion of drugs and TPN is emphasized by an unforeseen 62 
micro-precipitate generated by addition of increasing amounts of micronutrients, yet 63 
within recommended range, to the TPN.  64 
 65 
INTRODUCTION 66 
Infants and children require varying amounts of nutrients at different stages due to their 67 
continuous growth and development[1-2]. There has been an increased focus on standardized 68 
total parenteral nutrition (TPN) formulas, hospital-compounded and commercial admixtures, 69 
as they have been shown to be well-tolerated, easy to use and reduce the risk of serious 70 
mistakes[3-4]. Several benefits have been demonstrated also for preterm infants; recommended 71 
nutrition intake and weight gain can be obtained using standardized AIO formulas[5].  72 
Neonates in intensive care units often receive complex therapy with many drugs in 73 
addition to TPN, so Y-site administration can be desirable. However, TPN admixtures contain 74 
more than 50 different components, and physicochemical interactions leading to formation of 75 
precipitates and/or emulsion destabilization are quite possible if mixed with drugs. In the 76 
worst-case scenario particles and large oil droplets might cause blockage of blood vessels and 77 
even death if infused[6-7]. Documented compatibility data for TPN and drugs in Y-site is 78 
important in order to provide safe care for the patients. Extrapolation of existing compatibility 79 
data of drugs and TPN admixtures for older children and adults should be done with care 80 
because of differences in TPN composition, drug concentrations etc. The aim of this study was 81 
to obtain Y-site compatibility data for drugs and one standard TPN admixture used in preterm 82 
infants in Norway. Due to the observation of micro-precipitates in the admixture after addition 83 
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of trace elements, investigation of the effect of different trace element concentrations on the 84 
risk of precipitation in TPN developed as a sub goal. 85 
 86 
MATERIALS AND METHODS 87 
Materials 88 
 The TPN admixture was intended for peripheral or central administration to preterm 89 
infants from four days of age. This admixture can be ordered from Fresenius Kabi or 90 
compounded locally in the hospital pharmacy. Table 1 shows an overview of the ingredients 91 
of this admixture prepared in a local pharmacy in an ethyl vinyl acetate (EVA) monolayer bag 92 
(FrekaMix®, Fresenius Kabi). Drugs and concentrations tested are also shown in Table 1. 93 
Ceftazidime and fosphenytoin were reconstituted in glucose 50 mg/ml, and ampicillin and 94 
furosemide in NaCl 9 mg/ml. Fluconazole, metronidazole and paracetamol were used 95 
undiluted. 96 
 97 
  98 
 6 
Table 1: Overview of the ingredients constituting the TPN admixture prepared at the local 99 
hospital pharmacy, and drugs and concentration tested in simulated Y-site 100 
Product 













Vaminolac® Fresenius Kabi 16HK0133; 16HB0237  
Glucose 500 mg/ml Fresenius Kabi 121AH31; 12HKH17  
Water for injection Local pharmacy 14L08BD; 15B24BH  
Glycophos® Fresenius Kabi 12HKL28; 12HFL27  
Magnesium sulphate 1 mmol/ml B.Braun 15035012; 14377012  
Potassium chloride 1 mmol/ml B.Braun 144118091; 14423012; 14251013  
  Calcium chloride 1 mmol/ml B.Braun 15155036; 14412035; 13503035  
  Smoflipid®* Fresenius Kabi 16HK0062 
Trace 
elements 
Peditrace® Fresenius Kabi 12HFL07, 12HLL97 







Vitalipid® Infant* Fresenius Kabi 10HA2297; 10HK2215 
Drugs  
Ampicillin sodium 50 mg/ml Bristol-Myers Squibb 
3C02634, 4L02584, 5C03610, 
3F02259, 3J01732 
Ceftazidime pentahydrate 40 mg/ml Fresenius Kabi 18H3210 
Fluconazole 2 mg/ml B.Braun 13212418, 14384404 
Fosphenytoin sodium 10 mg/ml (given 
in phenytoin sodium equivalents) 
Pfizer J76024, H74522, L58188 




Metronidazole 5 mg/ml B.Braun 143448131, 131218131 




* For precipitation testing the lipid emulsion was substituted with water for injection and vitamins were omitted.   101 
 102 
Methods 103 
The full composition of two versions of the TPN admixtures used can be viewed in 104 
Table 2. For the assessment of potential precipitation the lipid emulsion was substituted with 105 
water for injection, and no vitamins were added to the bag[8], in order to avoid camouflage of 106 
particles by the white emulsion and strongly colored vitamins. This version was referred to as 107 
TPNaq. For investigation of emulsion stability the admixture including lipid and vitamins was 108 
compounded[8], and this version is referred to as TPN. Additions of micronutrients were made 109 
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in the highest recommended concentrations informed by Fresenius Kabi. However, in TPNaq 110 
used in drug compatibility assessments only 8 ml Peditrace per L was added (see result section).   111 
  112 
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Table 2: Composition of the two versions of TPN admixture: TPNaq, where the lipids are 113 
replaced by water for injections (contains no vitamins) and TPN containing all additives. 114 
 Ingredients Per liter TPNaq Per liter TPN 
Lipids (g) - 23.6 
     Olive oil  - 25% 
     Soybean oil - 30% 
     MCT - 30 % 
     Fish oil  - 15 % 
Glucose anhydrous (g) 56.4 54.2 
Amino acids total (g) 27.5 26.4 
Alanine (g) 2.7 2.6 
Arginine (g) 1.7 1.7 
Aspartic acid (g) 1.7 1.7 
Cysteine (g) 0.4 0.4 
Glutamic acid (g) 3.0 2.9 
Glycine (g) 0.9 0.9 
Histidine (g) 0.9 0.9 
Isoleucine (g) 1.3 1.3 
Leucine (g) 2.9 2.8 
Lysine (g) 2.4 2.3 
Methionine (g) 0.5 0.5 
Phenylalanine (g) 1.1 1.1 
Proline (g) 2.4 2.3 
Serine (g) 1.6 1.5 
Taurine (g) 0.1 0.1 
Threonine (g) 1.5 1.5 
Tryptophan (g) 0.6 0.6 
Tyrosine (g) 0.2 0.2 
Valine (g) 1.5 1.5 
Sodium (mmol) 16.0 16.0 
Potassium (mmol) 16.0 15.4 
Magnesium (mmol) 2.0 1.9 
Calciuma (mmol) 4.6 4.5 
Phosphateb (mmol) 8.0 10.3 
Chloride (mmol) 25.3 24.3 
Sulphate (mmol) 2.0 1.9 
Peditrace®c  (ml) 8d 14.5d 
     Zink chloride (mg) 4.1 7.4  
     Copper chloride (2H2O) (mg)  0.4e 0.8f 
     Manganese chloride (4H2O) (mg)  0.03 0.1 
     Sodium selenite anhydrous (mg)  0.03 0.1 
     Sodium fluoride (mg)  1.0 1.8 
     Potassium iodide (mg)  0.01 0.02 
Soluvit®c (vials) - 2.9 
Vitalipid® infantc (ml) - 33.4 
 115 
a: calcium chloride as calcium source;  116 
b: from glycerophosphate, the emulsion and Vitalipid® infant;  117 
c: micronutrient additives 118 
d: corresponds to 0.8 and 1.5 ml trace elements per. 100 ml respectively 119 
e: corresponds to 160 µg/L of Cu2+ 120 
f: corresponds to 290 µg/L of Cu2+ 121 
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 Some of the same drugs was previously studied in combination with TPN admixtures 122 
for neonates and older children in our set-up[9]. A range of relevant mixing ratios of drug+TPN 123 
were calculated in the same way as described earlier[9] to mimic different mixing ratios in the 124 
infusion line. Doses of drugs and TPN for preterm infants (weight 200 g - 2 kg) were used in 125 
the calculations. ESPEN/ESPGHAN and national guidelines were consulted in order to 126 
identify a relevant volume of TPN[1,10]. An infusion time of 8 and 24 hours were used to 127 
calculate the infusion rate of TPN. Eight hours are probably too fast for most preterm infants, 128 
but was included to constitute an extreme. The BNF for children, national guidelines, the 129 
Norwegian Medicines for Children network’s reconstitution tables[10-13] and SmPC were 130 
used to identify appropriate doses and infusion times of the drugs. Drug concentrations were 131 
chosen based on suggestions by clinicians and reconstitution tables[13]. Finally, the infusion 132 
rate of the drug was divided by the infusion rate of TPN to obtain the mixing ratio. Mixing 133 
ratio 1+1 plus the two most extremes (high drug:low TPN and low drug:high TPN) were chosen 134 
to best cover the full range of relevant mixing ratios. If no mixing ratio with excess drug was 135 
identified this way, two mixing ratios with excess of TPN were chosen as an alternative[9].  136 
Samples of drug and TPN were mixed in a laminar airflow cabinet by addition of TPN 137 
to the drug in sterile 50 ml polypropylene centrifuge tubes (Corning Incorporated, New York, 138 
USA). For visual examinations clean and sterilized glass tubes were used (Scherf Präzision 139 
Europa GmbH, Meiningen, Germany). Drugs and TPNaq were filtered 0.22 µm before mixing. 140 
TPN (with lipids) was not filtered. The samples were tested as soon as possible (within one 141 
hour) and again four hours after mixing. The visual examinations were in addition performed 142 
24 hours after mixing. 143 
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The possible influence of adding trace elements on precipitation in pure TPNaq was 144 
investigated by adding an increasing amount of trace elements (zero to maximum amount 145 
stated by manufacturer).  146 
A panel of test methods for assessment of precipitation and emulsion stability was 147 
employed (Table 3)[8]. Before mixing with drug, characterization of the drug-free TPNaq and 148 
TPN was performed to obtain base line values. The experiments were conducted under ambient 149 
laboratory conditions.  150 
 151 
  152 
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Table 3: Overview of test methods for assessment of physical compatibility between TPN and 153 
parenteral drugs and the acceptance criteria applied[8]. PFAT5 = volume weighted percentage 154 
of fat droplets above 5 µm. FNU = formazin nephelometry units. V.W. MDD = volume 155 
weighted mean droplet size. 156 
 157 
Methods for detection of potential 
precipitates in mixed samples 
(drug+ TPNaq) 
Acceptance criteria / points to consider 
Sub-visual particle counting by light 
obscurationa 
Particle counts  < 1000-2000/ml ≥ 0.5 µm[8], and 
large particles not exceeding Ph.Eur. limits for large 
volume parenterals[14]. 
Turbidity measured by turbidimeterb Turbidity < 0.20-0.30 FNU (taking into consideration 
background turbidity of unmixed samples)[8] 
Visual examination against black 
background with Tyndall beamsc 
No signs of visible particles or Tyndall effect[8, 15]. 
pH measured by pH-meterd Evaluation of risk of precipitation of drug and/or 
calcium phosphate.  
Methods for assessment of emulsion 
stability in mixed samples  
(drug+ TPN) 
Acceptance criteria / points to consider 
MDD measurements;  
laser diffractione  
V.W. MDD should be <500 nm.  
Size fraction (%) > 5 µm should be zero[16].  
PFAT5 calculated based on droplet size 
measurements from light obscurationa 
PFAT5 < 0.40 %[16, 17] 
pH measured by pH-meterd pH < 5.5 might be an indication of increased risk of 
emulsion destabilization[17] 
a: Accusizer 780 Optical Particle Sizer, Nicomp PSS, Santa Barbara, USA;  158 
b: 2100Qis Turbidimeter, Hach Lange GmbH, Düsseldorf, Germany;  159 
c: fiber optic light source (Schott KL 1600 LED, Mainz, Germany) and red pocket laser pointer (630-650 nm, 160 
max output <1 mW);  161 
d: Metrohm 744 pH Meter, Metrohm AG, Herisau, Switzerland;  162 
e: Mastersizer 2000 and Hydro 2000G sample dispersion unit, Malvern Instruments, Worcestershire, UK  163 
 164 
 165 
Sub-visual particles were counted using light obscuration (Accusizer 780 Optical 166 
Particle Sizer, Nicomp PSS, Santa Barbara, USA). The sensor type was LE-400-05 set in 167 
summation mode, measuring particles from 0.5 to 400 μm in 15 ml of undiluted sample[8]. 168 
The total particle count/ml ≥ 0.5 μm and the amount of particles ≥ 10 and 25 μm per ml were 169 
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determined[8,14]. The background count of the centrifugation tubes was below 100 170 
particles/ml ≥ 0.5 μm[8]. 171 
The turbidity of the samples was measured in Formazin nephelometry units (FNU) 172 
using a Turbidimeter (2100Qis, Hach Lange GmbH, Düsseldorf, Germany). The sample was 173 
gently inverted a few times before measurements[8].   174 
The samples were studied visually against a black background with two light sources, 175 
a fiber optic light source (Schott KL 1600 LED, Mainz, Germany) and a red pocket laser 176 
pointer (630-650 nm, max output <1 mW). The samples were gently inverted to set possible 177 
particles in motion[8,15]. 178 
The pH of samples was measured with a pH meter (Metrohm AG, Herisau, 179 
Switzerland) calibrated with buffers of pH 4.00, 7.00 and 10.00. Compatibility was 180 
theoretically evaluated based on pH-values[8].  181 
 182 
The volume weighted mean droplet diameter and volume weighted percent of particles 183 
below 500 nm and 1 μm were estimated using laser diffraction (Mastersizer 2000 and Hydro 184 
2000G sample dispersion unit, Malvern Instruments, Worcestershire, UK). The dispersion 185 
unit was filled with Milli-Q-water and the samples (≈ 2 ml aliquot) were added to this. The 186 
sonication was turned off to avoid breaking up large droplets. The absorbance was set to 0.001 187 
and the refractive index to 1.46[8].  188 
Light obscuration was used to estimate the PFAT5% of the fat emulsion, that is the 189 
percent of fat droplets above 5 microns in the large diameter tail[16,17]. The sensor was set in 190 
extinction mode and the detection threshold at 1.80 μm. A 40 ml glass beaker was used to 191 
dilute the samples, and Milli-Q-water as the dilution medium. Samples were collected with a 192 
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micropipette and diluted to concentrations below the instrument’s coincidence limit of 9000 193 
particles/ml, using dilution factors of 1:300–1200 (sample:water). The samples were stirred for 194 
60 seconds prior to measurements and during measurements with a magnetic stirrer embedded 195 
in the instrument. The sample withdrawal from the diluted emulsions was 15 ml. The counts 196 
were distributed over 128 channels, and the equivalent spherical volumes of the oil droplets 197 
were calculated. The density of oil used in calculations was 0.92 g/ml and the final fat 198 
composition 0.027 g/ml (including fat from Vitalipid® Infant)[8]. The following equation was 199 
used to calculate PFAT5[17]: 200 
 201 
𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 =  
[𝐏𝐏𝐓𝐓𝐓𝐓 (𝐜𝐜𝐜𝐜𝟑𝟑) 𝐱𝐱 𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃 (𝐠𝐠/𝐜𝐜𝐦𝐦) 𝐱𝐱 𝐃𝐃𝐃𝐃𝐦𝐦𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃 𝐟𝐟𝐟𝐟𝐜𝐜𝐃𝐃𝐃𝐃𝐟𝐟]
[𝐓𝐓𝐟𝐟𝐜𝐜𝐒𝐒𝐦𝐦𝐃𝐃 𝐯𝐯𝐃𝐃𝐦𝐦𝐃𝐃𝐜𝐜𝐃𝐃 (𝐜𝐜𝐜𝐜𝟑𝟑)𝐱𝐱 𝐏𝐏𝐃𝐃𝐃𝐃𝐟𝐟𝐦𝐦 𝐟𝐟𝐟𝐟𝐃𝐃 𝐜𝐜𝐃𝐃𝐜𝐜𝐒𝐒𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃 𝐠𝐠/𝐜𝐜𝐦𝐦]
 202 
 203 
TSV= total spherical volume, number of particles counted x ESV (equivalent spherical volume; 204 
ESV (equivalent spherical volume) =  




Density = density of oil used in the emulsion 207 
Sample volume = the amount of diluted sample measured, here 15 ml 208 
Final fat composition = the amount of lipid in grams/ml in the TPN admixture  209 
 210 
Statistical evaluations: calculation of means and standard deviations were performed. 211 
Compatibility was evaluated theoretically (pH/physico-chemical properties of drugs/TPN) 212 
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and according to stated acceptance criteria and negative controls (base line). An overall 213 
assessment of these factors was considered more appropriate than isolated statistical analysis.   214 
 215 
 216 
RESULTS AND DISCUSSIONS 217 
 218 
Characterization of TPNaq without added drug, and investigation 219 
of the effect of added trace elements on precipitation 220 
When the highest recommended addition of trace elements (1.5 ml Peditrace®/100 ml) 221 
was added to TPNaq, fine powdery particles were seen using Tyndall light, and both the sub-222 
visual particle counts and the turbidity indicated ongoing precipitation in TPNaq (Figure 1). 223 
Immediately after filtration of the TPNaq samples into the test tubes, the sub-visual particle 224 
counts were ≈1000 particles/ml, but they increased dramatically in number (≈14.000 225 
particles/ml) over the observation time of four hours. Particle sizes were mostly < 1 µm and 226 
the particle concentration of 10 and 25 µm particles were well below the Ph.Eur limits[14]. A 227 
correlation was observed between the amount of added trace elements and the extent of 228 
precipitation (Figure 1). This was also the case for the turbidity measurements, although the 229 
FNU values were above the acceptance limit also right after filtration (Figure 1). In visual 230 
examination small amounts of haze could be identified, increasing over four hours. After about 231 
24 hours most of the haze seemed to have disappeared in the sample tubes. Furthermore, a 232 
brownish color was noticed on the syringe filters used to filter the samples (Figure 2), also 233 
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disappearing over time. During the course of the shelf life of the mixture, the precipitation in 234 
the TPNaq bag seemed to gradually decrease. In an attempt to avoid precipitation, lower 235 
amounts of trace elements (1 ml/100 ml and 0.8 ml/100 ml) were added. 0.8 ml Peditrace®/100 236 
ml corresponds to “normal” use instead of the maximum limits (Table 2). The particle counts 237 
were much lower compared to the 1.5 ml/100 ml samples, however the turbidity was not 238 
acceptable and haze could still be seen in Tyndall light (Figure 1). 239 
Detection of brown precipitates on in-line-filters used during administration of TPN 240 
admixtures have been reported, possibly caused by an interaction between copper and 241 
cysteine[18-20]. The preterm admixture contained cysteine, which is typically added as a semi 242 
essential amino acid in pediatric TPN[1], and copper was introduced with the trace elements. 243 
Thibault suggests a limit of 157 µg copper per litre when using low pH, cysteine containing 244 
amino acid solutions[19] which is in the same order of magnitude as in the current study. 245 
However, no similar precipitate was detected in our previous study with a TPN admixture 246 
containing higher concentrations of trace elements and a similar concentration of cysteine[9]. 247 
Foinard et al. observed a stronger color on the filters after filtration of the complete TPN 248 
admixture compared to filters used for filtration of a solution containing only amino acids and 249 
trace elements, even though the latter mix contained a higher concentration of cysteine and 250 
trace elements[20]. This suggests that the concentration of trace elements and cysteine are not 251 
the only influencing factors. Additional factors such as pH, redox conditions, ion 252 
concentration, combination of metal ions, mixing order, temperature, glucose, derivate of 253 
cysteine, packaging (multilayer versus monolayer), light, presence of vitamins etc. have been 254 
discussed[18, 21-23].  255 
 Fresenius Kabi performed a retest on this particular admixture in a multilayer bag, 256 
without finding any precipitate (personal e-mail correspondence, Hege Børringbo, Fresenius 257 
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Kabi). The use of different packaging might have prevented the precipitation. On the other 258 
hand, Allwood and co-workers found the copper cysteinate (or copper sulphide) precipitate to 259 
occur more easily in multilayer bags[23]. However, consulting other authors describing this 260 
precipitation we learned that, Foinard and colleagues[20] used a multilayer bag (personal e-261 
mail correspondence, Dr. Aurélie Foinard), and Thibault[19] used a monolayer EVA bag 262 
(personal e-mail correspondence, Dr. Maxime Thibault), and both found this precipitate. 263 
Another aspect to consider is that studies have shown that TPN ingredients might be 264 
contaminated to different extent by trace elements[24], which could have influenced the 265 
outcomes in our study as well. Clearly, this is a complex matter and elucidating all influencing 266 
factors needs further research. Unfortunately, the nature of the precipitate and the actual copper 267 
content of the raw materials and final admixtures were not analyzed. It should be noted that the 268 
admixture used in this study is not identical to the one delivered by Fresenius Kabi. The 269 
concentrations are the same, however raw materials and bag used are different.  270 
 The possible clinical significance of the observed precipitate is not known. It has been 271 
discussed that such a precipitate might affect the availability of copper and cysteine and lead 272 
to symptoms of deficiency over time[20]. It is also possible that infusion of the particles formed 273 
could have a harmful effect. The SmPC of the cysteine containing amino acid solution 274 
Primene® (Baxter) includes an instruction to use a final filter during administration of 275 
Primene® and trace elements in order to remove particles that may form with e.g. copper, and 276 
further recommends to perform blood levels of copper (when medically relevant) if 277 
discoloration of filters are noted[25]. 278 
Trace elements in the concentration 0.8ml/100 ml, corresponding to “normal” amount 279 
of trace elements, was chosen for the compatibility testing with drugs. Base line values for the 280 
TPNaq and TPN compositions outlined in Table 2, can be viewed in Table 4. Base line values 281 
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for the drugs in the same reconstituted concentrations were reported in a previous work[9]. As 282 
can be seen in Table 4 the sub-visual particle counts were low, but high turbidity and small 283 
amounts of visual micro-precipitates were still present in TPNaq. Since the test results after 284 
mixing with drug would be affected, this has to be kept in mind for the interpretation of the 285 
results. For tests on the emulsion stability, the maximum amounts of trace elements were added 286 
(Table 2). It is not known whether the precipitate was present in the admixture containing lipid, 287 




Table 4: Results from the investigation of possible precipitation and emulsion stability following the mixing of drug and TPN (n≥ 3), V.W. MDD 291 
(volume weighted mean droplet diameter) and % size fractions: n=1 with multiple runs. Mix ratios denotes drug+TPNaq or drug+TPN, respectively. Shaded areas highlight 292 
values that might indicate an incompatible mix.  293 
* All tests were performed with paracetamol from B.Braun, except from laser diffraction measurements, where the paracetamol was from Fresenius Kabi. **Particle counts above 10 and 25 µm are not shown, as the 294 







Investigation of possible formation of precipitation with TPNaq Testing of emulsion stability with TPN 
**Particles/ml ≥ 0.5 




























0h 4h 0h 4h 0h 4h 24h 0h 4h 0h 4h 4h 4h 4h 0h 4h 
Baseline 
(TPNaq/TPN) - 17  ± 15 136 ± 40 0.32 ± 0.17 0.86 ± 0.50 +/- +/- - 5.89 5.89 0.11 ± 0.01 0.18 ± 0.02 82 100 375 5.89 5.89 
Ampicillin 
50mg/mla 
1+10 336 ± 219 113 ± 98 0.28 ± 0.04 0.23 ± 0.06 + + + 6.91 6.81 0.07 ± 0.00 0.10 ± 0.01 82 100 374 6.92 6.77 
1+1 100 ± 36 1932 ± 200 0.45 ± 0.17 0.67 ± 0.06 + + + 7.95 7.92 0.08 ± 0.01 0.04 ± 0.01 83 100 373 8.03 7.92 
2+1 86 ± 4 2287 ± 591 0.96 ± 0.10 1.03 ± 0.16 + + + 8.16 8.19 0.07 ± 0.00 0.04 ± 0.01 85 100 370 8.23 8.16 
Ceftazidime  
40 mg/mlb 
1+10 55 ± 16 12 ± 6 0.10 ± 0.02 0.20 ± 0.02 - - + 6.04 6.00 0.09 ± 0.01 0.23 ± 0.02 83 100 369 6.00 6.04 
1+1 19 ± 5 18 ± 2 0.12 ± 0.02 0.12 ± 0.03 - - - 6.48 6.42 0.12 ± 0.07 0.04 ± 0.03 87 100 360 6.63 6.71 
1+2 27 ± 12 13 ±6 0.10 ± 0.01 0.10 ± 0.01 - - +/- 6.33 6.28 0.09 ± 0.02 0.14 ± 0.02 83 100 370 6.36 6.45 
Fluconazole 
2 mg/mlc 
1+10 381 ± 190 180 ± 12 0.16 ± 0.04 0.12 ± 0.01 + +/- - 5.85 5.86 0.14 ± 0.02 0.30 ± 0.06 82 100 378 5.84 5.85 
1+1 360 ± 165 85 ± 19 0.14 ± 0.02 0.09 ± 0.00 + +/- - 5.86 5.87 0.12 ± 0.01 0.29 ± 0.04 81 100 382 5.85 5.89 
9+1 92 ± 4 77 ± 26 0.08 ± 0.02 0.07 ± 0.01 - - - 5.85 5.87 0.10 ± 0.01 0.32 ± 0.28 80 100 385 5.88 5.90 
Fosphenytoin 
 10 mg/mlb 
1+50 135 ± 19 33 ± 4 0.10 ± 0.01 0.10 ± 0.01 - - - 5.94 5.96 0.11 ± 0.01 0.15 ± 0.04 82 100 374 5.91 5.92 
1+1 132 ± 14 27 ± 10 0.09 ± 0.02 0.18 ± 0.08 +/- +/- + 7.47 7.44 0.09 ± 0.00 0.04 ± 0.00 83 100 375 7.34 7.23 
5+1 54 ± 20 52 ± 25 0.08 ± 0.01 0.11 ± 0.01 - - - 8.21 8.25 0.09 ± 0.01 0.08 ± 0.01 82 100 378 8.14 8.07 
Furosemide 
2 mg/mla 
1+100 436 ± 215 105 ± 31 0.14 ± 0.05 0.10 ± 0.01 - - - 5.87 5.90 0.13 ± 0.03 0.24 ± 0.02 83 100 373 5.84 5.85 
1+1 561 ± 319 39 ± 16 0.13 ± 0.04 0.08 ± 0.00 +/- +/- +/- 5.94 5.98 0.10 ± 0.01 0.04 ± 0.01 83 100 372 5.90 5.93 
2+1 518 ± 284 51 ± 26 0.12 ± 0.02 0.09 ± 0.01 +/- +/- +/- 5.99 6.02 0.09 ± 0.01 0.04 ± 0.02 83 100 374 5.97 5.98 
Metronidazole 
 5 mg/mlc 
1+10 312 ± 82 218 ± 26 0.26 ± 0.14 0.27 ± 0.16 +/- +/- - 5.84 5.85 0.17 ± 0.03 0.35 ± 0.08 82 100 374 5.81 5.83 
1+1 302 ± 81 118 ± 28 0.18 ± 0.09 0.10 ± 0.02 +/- - - 5.63 5.65 0.16 ± 0.01 0.29 ± 0.05 82 100 377 5.60 5.62 
5+1 252 ± 25 109 ± 85 0.10 ± 0.01 0.10 ± 0.01 - - - 5.29 5.28 0.15 ± 0.05 0.27 ± 0.10 82 100 377 5.27 5.29 
Paracetamol* 
10 mg/mlc 
1+10 40 ± 1 42 ± 9 0.14 ± 0.01 0.13 ± 0.02 - - - 5.70 5.71 0.08 ± 0.00 0.20 ± 0.01 80 100 379 5.75 5.76 
1+1 13 ± 1 12 ± 4 0.35 ± 0.01 0.36 ± 0.02 + + + 5.30 5.31 0.09 ± 0.01 0.15 ± 0.01 83 100 374 5.33 5.33 




Characterization of TPN (with lipid) without added drug 296 
The lipid droplet size was as expected within the acceptance limits (Table 3 and 4). The 297 
PFAT5 was below 0.40 % and the V.W. MDD was well below 500 nm. Even though the 298 
admixture was judged to be stable, some creaming and/or flocculation was visible in the bag. 299 
Creaming can be reversed as opposed to coalescence, and the admixture might still be safe for 300 
infusion provided prior thorough mixing.   301 
 302 
Physical Y-site compatibility of drugs and TPNaq (without lipids 303 
and vitamins) 304 
All sub-visual particle counts were low after mixing with the different drugs, except for 305 
ampicillin where the particle count had increased considerably after four hours (Table 4). This 306 
is also described in previous studies[8-9], and is probably caused by calcium phosphate 307 
precipitation occurring when the pH-values increases above pKa2 of phosphoric acid at pH 308 
7.2[26]. Ampicillin has been found incompatible in some studies[27-28], and compatible in 309 
others[29-30]. Based on the current investigations ampicillin and the Preterm mix should be 310 
regarded as incompatible. 311 
The turbidity was above the acceptance limit (>0.20-0.30 FNU) for some mixing ratios 312 
of samples with ceftazidime, fosphenytoin, metronidazole and paracetamol (Table 4). 313 
Ceftazidime had a slightly increased turbidity after four hours in the mixing ratio 1+10, which 314 
might be due to the background noise of TPNaq. However, a clear precipitation and color 315 




that the increased turbidity also might be an initial warning of precipitation in progress due to 317 
the mixing of drug with high volume of TPNaq. Co-administration might, therefore, be 318 
discouraged, however, ceftazidime has been reported to be compatible in studies with other 319 
TPN admixtures[9, 28-30]. 320 
For fosphenytoin a somewhat high, but variable turbidity (high standard deviation) was 321 
measured four hours after mixing in mixing ratio 1+1. Although this in isolation could be 322 
explained by the background noise, particles were also detected by visual examination in some 323 
of the samples immediately and four hours after mixing. After 24 hours, a precipitate was 324 
obvious. Since fosphenytoin is formulated with an alkaline pH (8.6)[9], and buffered with 325 
trometamol (SmPC), the pH value was quite high (7.5) also after mixing with the Preterm mix. 326 
The precipitate might be calcium phosphate due to alkaline pH and/or degradation of the 327 
prodrug to the less soluble phenytoin[31]. In mixing ratio 5+1 there were no signs of 328 
precipitation, although the pH was 8.2. An explanation might be the lower concentration of 329 
TPN and therefore more dilution of calcium phosphate causing less chance of precipitation.  330 
The high turbidity observed in mixtures with metronidazole can presumably be 331 
explained by the background noise of the TPNaq. In visual examination the haze was very 332 
similar to the trace element-induced precipitate, and it seemed to diminish over time like the 333 
turbidity of the pure TPNaq stored in sample tubes. The paracetamol samples also showed 334 
increased turbidity and Tyndall effect in mixing ratio 1+1 and 1+2, but not in 1+10. In contrast 335 
to the above, these findings did not change over time and were also observed in the pure drug. 336 
Therefore, the opacity could be attributed to the drug itself and not a sign of incompatibility[8-337 
9]. Fluconazole showed some signs of particles/Tyndall effect during visual examination after 338 
mixing with TPNaq, but no other signs of precipitation was detected (Table 4). The haze in 339 




was not detectable after 24 hours. Therefore, disregarding the trace element-induced 341 
precipitations and background noise of pure drug, metronidazole, paracetamol and fluconazole 342 
were probably compatible with the TPNaq admixture. This is supported by studies with other 343 
admixtures[9, 28-30, 32-33]. 344 
The appearance of the particles observed in TPNaq mixed with furosemide was 345 
different. Traces of particle formation were occasionally encountered during visual 346 
examination, especially in samples examined 4 and 24 hours after mixing. The pH after mixing 347 
was close to that of TPNaq, and since furosemide might precipitate in acidic solution it is 348 
probably safest to avoid mixing with TPN. This is in correspondence with the findings with 349 
one TPN admixtures for children (Numeta G16E) previous tested in our set-up[9], and also 350 
with one of Trissel and colleagues’ publications[29]. Other reports have concluded with 351 
compatibility[28,30,33], including the results for the other TPN admixture for older children 352 
(OlimelN5E) tested in our previous mentioned report[9]. The different conclusions might be 353 
explained by differences in pH of the TPN products. The more acidic pH of the admixtures for 354 
the smallest children could result in an increased risk of precipitating furosemide.  355 
 356 
Physical Y-site compatibility of drugs and TPN (with lipid) 357 
Regarding emulsion stability there were only a few occasions where the PFAT5 values 358 
of drug+TPN mixtures were above the acceptance criteria of < 0.40 % , that is if the standard 359 
deviations are included (Table 4). After mixing with fluconazole, metronidazole and 360 
paracetamol the PFAT5 limit was sometimes crossed. As mentioned, some creaming was 361 




might be intrinsic to the admixture itself. Scrutinizing the different mixing ratios of drug+TPN 363 
for all drugs, the PFAT5 was high also in mixing ratios containing high volume of TPN and 364 
low volume of drug. It is less likely that such a small amount of drug would destabilize the 365 
emulsion. Nevertheless, based on the current results, we cannot recommend co-administration 366 
of the Preterm mix with fluconazole, metronidazole or paracetamol.  367 
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FIGURES:  466 
 467 
Figure 1: Increasing sub-visual particle counts (A) and turbidity (B) of TPNaq as a consequence 468 
of stepwise addition of trace elements (Peditrace®) (n≥3). Sample preparation and 469 





Figure 2: Appearance of filters after filtration of the TPNaq admixture; without addition of 472 
trace elements (left) and with ≈ 1.5 ml/100 ml of trace elements (right).  A brown color could 473 
be seen on filters that had been in contact with the admixture containing trace elements. The 474 
color disappeared over time. 475 
 476 
